Age of patients

No definition available.

Name:	derm_AgeOfPatients
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of expense agreed to pay under the agreement.

+ References

No definition available.

+ Details

Name:	derm_AmountOfExpenseAgreedToPayUnderAgreement
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of contingent amount payable under asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementContingentAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payments to be paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The period of royalty payments in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementPeriodOfRoyaltyPayments
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront fees paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementUpfrontFees
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of royalty payments in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementsPercentageOfRoyaltyPayments
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of milestone payments payable which is triggered due to approval received from FDA under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementMilestonePaymentObligationTriggeredOnReceiptOfFdaApproval
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of royalties payable on net sales under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementPercentageOfRoyaltiesPayableOnNetSales
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold additional contingent regulatory and commercial milestone payments payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementThresholdAdditionalContingentRegulatoryAndCommercialMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total amount payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementTotalAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The period of renewable mutual agreement term .

+ References

No definition available.

+ Details

Name:	derm_RenewableMutualAgreementTerm
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of termination written notice to other party. .

+ References

No definition available.

+ Details

Name:	derm_TerminationWrittenNoticePeriodToOtherParty
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_EmrosiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_QbrexzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForFirstTwoYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=derm_EliLillyAndCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_LicenseAndSupplyAgreementWithDrlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_AccutaneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSES ACQUIRED (Details) - USD ($) $ in Millions	1 Months Ended
LICENSES ACQUIRED (Details) - USD ($) $ in Millions	Jun. 30, 2021	Mar. 31, 2021	Jul. 31, 2020	Nov. 04, 2024
Emrosi Agreement
LICENSES ACQUIRED
Amount payable	$ 10.0
Emrosi Agreement \| Subsequent Event
LICENSES ACQUIRED
Amount received from FDA under the license, collaboration, and assignment agreement				$ 15.0
Emrosi Agreement \| Minimum
LICENSES ACQUIRED
Percentage of royalties payable on net sales	10.00%
Emrosi Agreement \| Maximum
LICENSES ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable	$ 140.0
Percentage of royalties payable on net sales	20.00%
Asset purchase agreement \| Qbrexza
LICENSES ACQUIRED
Age of patients		9 years
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
LICENSES ACQUIRED
Period of royalty payments		2 years
Asset purchase agreement \| Minimum \| Royalty payment percentage for first two years \| Qbrexza
LICENSES ACQUIRED
Percent of royalty payments		30.00%
Asset purchase agreement \| Minimum \| Royalty payment percentage for thereafter \| Qbrexza
LICENSES ACQUIRED
Percent of royalty payments		12.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for first two years \| Qbrexza
LICENSES ACQUIRED
Percent of royalty payments		40.00%
Asset purchase agreement \| Maximum \| Royalty payment percentage for thereafter \| Qbrexza
LICENSES ACQUIRED
Percent of royalty payments		19.00%
Asset purchase agreement \| Eli Lilly and Company \| Qbrexza
LICENSES ACQUIRED
Upfront fees		$ 12.5
Milestone payments payable		$ 144.0
License and supply agreement With DRL \| Accutane
LICENSES ACQUIRED
Amount of expense agreed to pay under the agreement			$ 5.0
Contingent amount payable			$ 17.0
Term of accutane			10 years
Termination accutane agreement period			180 days